Amylin (AMLN) Bidding Intensifies; Sale Expected in July

June 5, 2012 6:57 AM EDT Send to a Friend
Get Alerts AMLN Hot Sheet
Trade AMLN Now!
Amylin Pharmaceuticals (Nasdaq: AMLN) shares are popping early Tuesday morning, following reports of more M&A chatter for the multi-billion dollar biopharma.

According to Bloomberg, second-round bids for Amylin have drawn a value of $25 to $29 per share.

First-round proposals were made by AstraZeneca (NYSE: AZN), Sanofi (NYSE: SNY), Merck (NYSE: MRK), and Bristol-Myers (NYSE: BMY). Pfizer (NYSE: PFE) is said to have dropped out of the bidding process.

In March, Amylin rejected a $22 billion bid from Bristol-Myers.

Top-end bids would value Amylin at $4.7 billion. Final submissions are expected to be made by the end of June with a sale likely to take place in July.

Bidders are currently receiving presentations from senior-level executives as well as correspondence Amylin has had with the FDA.

Shares of Amylin are up over 4 percent in early trading. Shares closing at $26.63 Monday mean bids could reach an additional 8.8 percent premium.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Mergers and Acquisitions, Rumors

Add Your Comment